Natus Medical Inc. (BABY) Stake Decreased by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC decreased its stake in Natus Medical Inc. (NASDAQ:BABY) by 1.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 486,155 shares of the company’s stock after selling 7,252 shares during the period. Natus Medical accounts for approximately 1.1% of Rice Hall James & Associates LLC’s portfolio, making the stock its 21st largest position. Rice Hall James & Associates LLC owned approximately 1.50% of Natus Medical worth $18,377,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of BABY. Invictus RG bought a new stake in shares of Natus Medical during the first quarter valued at about $148,000. Kennedy Capital Management Inc. raised its stake in shares of Natus Medical by 88.4% in the first quarter. Kennedy Capital Management Inc. now owns 202,553 shares of the company’s stock valued at $7,784,000 after buying an additional 95,022 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of Natus Medical by 6.2% in the first quarter. Lazard Asset Management LLC now owns 135,758 shares of the company’s stock valued at $5,217,000 after buying an additional 7,951 shares during the last quarter. State Street Corp raised its stake in shares of Natus Medical by 2.2% in the first quarter. State Street Corp now owns 674,379 shares of the company’s stock valued at $25,914,000 after buying an additional 14,617 shares during the last quarter. Finally, Motley Fool Wealth Management LLC raised its stake in shares of Natus Medical by 9.4% in the first quarter. Motley Fool Wealth Management LLC now owns 74,290 shares of the company’s stock valued at $2,855,000 after buying an additional 6,402 shares during the last quarter. Institutional investors own 87.92% of the company’s stock.
Natus Medical Inc. (NASDAQ:BABY) traded up 1.58% on Monday, reaching $39.91. 485,955 shares of the company were exchanged. The firm has a 50-day moving average of $40.41 and a 200 day moving average of $36.82. The firm has a market capitalization of $1.29 billion, a P/E ratio of 34.41 and a beta of 0.78. Natus Medical Inc. has a 12-month low of $29.54 and a 12-month high of $51.05.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.03. The business had revenue of $96 million for the quarter, compared to analysts’ expectations of $92.71 million. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.34 earnings per share. On average, equities analysts predict that Natus Medical Inc. will post $1.58 earnings per share for the current year.
Several brokerages have recently issued reports on BABY. Raymond James Financial Inc. upgraded shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target for the company in a research note on Tuesday, September 13th. Zacks Investment Research lowered shares of Natus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, September 28th.
In other news, insider James B. Hawkins bought 10,000 shares of the company’s stock in a transaction dated Wednesday, September 28th. The shares were purchased at an average price of $38.48 per share, for a total transaction of $384,800.00. Following the completion of the purchase, the insider now owns 459,725 shares in the company, valued at approximately $17,690,218. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.80% of the stock is currently owned by insiders.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.